TriangleBevacizumab (NCT01269853)
Bevacizumab trial for Glioblastoma Multiforme (NCT01269853). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Glioblastoma returns in essentially every patient. At recurrence, bevacizumab is given by vein to starve the tumor of blood vessels, but the brain's barrier lets little of it through.
The idea: skip the barrier. Thread a catheter to the artery feeding the tumor, open the barrier briefly, and deliver the drug there.
At Lenox Hill in New York, neurosurgeons pass a microcatheter from the groin into the cerebral artery supplying the tumor, infuse mannitol to loosen the blood-brain barrier for minutes, then deliver bevacizumab straight in. An earlier trial showed one such dose was safe. This study repeats it at each progression, with or without intravenous dosing between.
John Boockvar leads it, for relapsed glioblastoma and anaplastic astrocytoma. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.